International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 3 (May-June 2025) Submit your research before last 3 days of June to publish your research paper in the issue of May-June.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 7 Issue 3
May-June 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

A Research Paper On: Capecitabine as a Targeted Oral Anticancer Agent : Evaluation of Capecitabine(Tablet) and Therapeutic Assessment.

Author(s) Mr. Vishal S. Lavgale, Dr. Sunil S. Jaybhaye, Prof. Saurabh M. Bondre
Country India
Abstract The present research work focused on the detailed study of the oral gastro-retentive dosage forms (GRDFs) of capecitabine, including its drug profile and preformulations studies and comparison of therapeutic potential as a antineoplastic agent with the other antineoplastic agents. Marketed tablet formulations were evaluated based on various physicochemical parameters. Additionally, the therapeutic potential of capecitabine was compared with other anticancer drugs. Capecitabine, a prodrug of 5-fluorouracil (5-FU), has become a cornerstone in the treatment of various solid tumors, particularly colorectal, breast, and gastric cancers. Its unique mechanism of action involves a selective conversion into 5-FU within tumor cells through a series of metabolic steps. This targeted activation helps to minimize systemic toxicity while maximizing anticancer efficacy. Capecitabine has shown substantial effectiveness not only as a single-agent therapy but also in combination regimens, enhancing its versatility in clinical applications. Current research also focuses on identifying predictive biomarkers for better patient selection and exploring novel therapeutic combinations to improve treatment outcomes. These efforts support its potential as a personalized anticancer therapy in the era of precision medicine. In this study, the physicochemical and preformulation studies of capecitabine tablets were carried out, and the prepared formulations were evaluated thoroughly.
Keywords Capecitabine (CPC), In vitro dissolution study, Therapeutic Potential of Capecitabine.
Field Medical / Pharmacy
Published In Volume 7, Issue 3, May-June 2025
Published On 2025-05-29
DOI https://doi.org/10.36948/ijfmr.2025.v07i03.46294
Short DOI https://doi.org/g9mn7h
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 3Cover Page Vol 7 Isu 2Cover Page Vol 7 Isu 1

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com